Kenya - English - Pharmacy and Poisons Board

clomifene citrate - tablet - each tablet contains clomifene citrate b.p 50mg - androstanolone

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clomifene citrate -

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - clomifene citrate - tablets - clomifene citrate 50 mg - clomifene - in women : ovulatory failure in patients desiring pregnancy.

Malta - English - Medicines Authority

jv healthcare limited - clomifene citrate - tablet - clomifene citrate 50 mg - sex hormones and modulators of the genital system

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - clomifene citrate 50mg - tablet - 50 mg - active: clomifene citrate 50mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone powdered cellulose

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clomifene citrate 50mg - tablet - 50 mg - active: clomifene citrate 50mg excipient: amylodextrin lactose monohydrate magnesium stearate maize starch sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clomifene citrate 50mg;   - tablet - 50 mg - active: clomifene citrate 50mg   excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified talc quinoline yellow sucrose

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - clomiphene citrate - tablet - 50 milligram(s) - ovulation stimulants, synthetic; clomifene

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - toremifene citrate, quantity: 88.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; povidone; maize starch - for the first line treatment of hormone-dependent metastatic breast cancer in postmenopausal women. it is not recommended for patients with oestrogen receptor negative tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; mannitol - treatment of breast cancer. genox is indicated for the treatment of breast cancer. primary reduction of breast cancer risk. genox is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).